Table 1.
General variables.
| Variable | All subjects n = 106 n (%) | Rheumatoid arthritis n = 52 n (%) | Osteoarthritis n = 54 n (%) | p-value | |
|---|---|---|---|---|---|
| Sex | Female | 80 (75.5) | 40 (76.9) | 40 (74.1) | 0.733 |
| SES | Low | 58 (54.7) | 27 (51.9) | 31 (57.4) | 0.571 |
| Comorbidities | AH | 9 (8.5) | 4 (7.7) | 5 (9.3) | 1.000a |
| Diabetes mellitus | 2 (1.9) | 2 (3.8) | 0 (0.0) | 0.238a | |
| Osteoporosis | 12 (11.3) | 8 (15.4) | 4 (7.4) | 0.195 | |
| Dyslipidemia | 5 (4.7) | 0 (0.0) | 5 (9.3) | 0.057a | |
| Hypothyroidism | 18 (17) | 6 (11.5) | 12 (22.2) | 0.143 | |
| Osteoarthritis | 81 (76.4) | 27 (51.9) | 54 (100) | 0.000 | |
| Fibromyalgia | 20 (18.9) | 0 (0.0) | 20 (37) | 0.000 | |
| Familial CVD - FDR with CVD | 51 (48.1) | 26 (50) | 25 (46.3) | 0.703 | |
| Familial autoimmunity | 30 (28.3) | 20 (38.5) | 10 (18.5) | 0.023 | |
| Physical activity | 67 (63.2) | 31 (59.6) | 36 (66.7) | 0.452 | |
| Lifestyle exposure | Tobaccob | 8 (7.5) | 3 (5.8) | 5 (9.3) | 0.716a |
| Coffee | 90 (84.9) | 47 (90.4) | 43 (79.6) | 0.122 | |
| Alcohol | 4 (3.8) | 3 (5.8) | 1 (1.9) | 0.358a | |
| Variable | All subjects c | Rheumatoid Arthritis c | Osteoarthritis c | p -value | |
| Age (years) | 57 (9) | 57 (9) | 57 (9) | 0.934 | |
| Waist circumference (cm) | 85 (10.5) | 82 (10.3) | 88.5 (10.3) | 0.000 | |
| Hip circumference (cm) | 101 (9) | 98.5 (7) | 102 (9.3) | 0.002 | |
| Waist-hip ratio | 0.856 (0.1) | 0.848 (0.1) | 0.875 (0.1) | 0.124 | |
| Weight (kg)d | 65.05 (9.48) | 61.78 (9.60) | 68.20 (8.3) | 0.000 | |
| Height (cm)d | 159.48 (8.46) | 158.57 (7.89) | 160.35 (8.96) | 0.283 | |
| BMI (kg/m2)d | 25.9 (5) | 24.74 (4) | 27.12 (5) | 0.000e | |
| Fasting plasma glucose (mg/dL) | 84 (13) | 82.5 (13) | 84 (15) | 0.173 | |
| Triglycerides | 1.57 (0.99)f 139 (88)g | 1.50 (1.02)f 133 (90.3)g | 1.61 (0.99)f 142.5 (88)g | 0.808 | |
| Total cholesterold | 6.12 (1.26)f 237 (48.54)g | 6.15 (1.17)f 237.98 (45.43)g | 6.10 (1.34)f 236.07(51.76)g | 0.410h | |
| HDL-c | 1.26 (0.53)f 49 (20.5)g | 1.29 (0.63)f 50 (24.3)g | 1.22 (0.53)f 47.5 (20.3)g | 0.726 | |
| LDL-cd | 4.01 (1.02)f 155.21 (39.36)g | 4.00 (0.95)f 155.01 (36.62)g | 4.01(1.09)f 155.40 (42.18)g | 0.480h | |
| CRP (mg/dL) | 0.400 (0.4) | 0.450 (1.2) | 0.300 (0.2) | 0.003 | |
| ESR (mg/dL) | 15 (12) | 18 (14) | 14 (7.5) | 0.004 | |
| Pain VAS | 6 (4) | 4.5 (4.8) | 7 (2.3) | 0.000 | |
| VAS GLOBAL | 3.5 (3) | 3 (3.8) | 4 (4) | 0.037 | |
| Fatigue VAS | 3 (6) | 2 (4.4) | 5 (6.6) | 0.008 | |
| RAPID3d | 11.72 (6.29) | 10.18 (6.67) | 13.21 (5.57) | 0.013h | |
| VAS Global EQ5D | 62.50 (30) | 70 (37.5) | 57.50 (40) | 0.023 | |
| EQ-5D-3L VAS score | 0.73 (0.22) | 0.73 (0.18) | 0.69 (0.22) | 0.043 | |
| EQ-5D-3L TTO score | 0.71 (0.33) | 0.78 (0.46) | 0.64 (0.56) | 0.020 | |
Fisher test was used;
Smoking cessation based on reference (82);
Median (Interquartile range);
Average (Standard deviation);
U-Mann-Whitney test;
mmo/L;
mg/dL;
t-Student test; AH, Arterial Hypertension; BMI, Body mass index; CRP, C-reactive protein; CVD, Cardiovascular Disease; EQ-5D-3L, European Quality of Life 5 Dimensions 3 Levels; EQ-5D-3L TTO score, European Quality of Life 5 Dimensions 3 Levels time trade-off score; EQ-5D-3L VAS score, European Quality of Life 5 Dimensions 3 Levels visual analog rating scale score; ESR, Erythrocyte sedimentation rate; FDR with CVD, First degree relative with Cardiovascular disease; HDL-c, High-density lipoprotein cholesterol; LDL-c, Low-density lipoprotein cholesterol; RAPID 3, Routine assessment of patient index data 3; SES, Socioeconomic Status; VAS Global EQ5D, Visual analog scale Global European Quality 5 Dimensions; VAS, Visual analog scale.